Answers are grounded in this paper and cite their sources.
Background The association between the early dynamics of hepatitis B surface antigen (HBsAg) and its subsequent clearance has been observed in patients with chronic hepatitis B (CHB). However, its relationship with other clinical outcomes remains poorly understood. Objective This study aimed to investigate the longitudinal trajectories patterns of HBsAg and their associations with hepatitis B e antigen (HBeAg) clearance in pediatric patients with CHB undergoing antiviral treatment. Methods A large retrospective cohort study was conducted on 402 pediatric patients with HBeAg-positive CHB. Latent class trajectory models (LCTM) were applied to examine HBsAg trajectories within the first six months of initiating antiviral therapy. Cox proportional hazard models were used to assess the associations between HBsAg trajectories and HBeAg clearance. Results Among the 402 participants, the median age was 5 years, with 249 (61.94%) being male. During a median follow-up of 19.03 months, 216 participants (53.73%) achieved HBeAg clearance. LCTM revealed three distinct HBsAg trajectory patterns: ‘trajectory 1’ (sustained stability, n=43, 10.7%), ‘trajectory 2’ (slow decline, n=195, 48.5%), and ‘trajectory 3’ (rapid decline, n=164, 40.8%). Patients in trajectories 2 and 3 had significantly higher probabilities of HBeAg clearance compared to those in trajectory 1 (adjusted hazard ratio [aHR] = 3.99, 95% CI, 2.20-7.22 for trajectory 2; aHR = 7.21, 95% CI, 3.65-14.24 for trajectory 3). Conclusions There is significant heterogeneity in the longitudinal changes of HBsAg levels among pediatric CHB patients with antiviral treatment. Approximately half of the patients exhibited a substantial HBsAg decline, which was associated with a higher likelihood of HBeAg clearance.
No takes yet. Share an insight, caveat, or question.
Ouyang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: